Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer.
World J Clin Cases
; 10(18): 6069-6081, 2022 Jun 26.
Article
em En
| MEDLINE
| ID: mdl-35949840
ABSTRACT
BACKGROUND:
Icotinib could have potential effect and tolerability when used sequentially with chemotherapy for advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).AIM:
To evaluate the efficacy and safety of chemotherapy followed by icotinib maintenance therapy as first-line treatment for advanced EGFR-mutated NSCLC.METHODS:
This multicenter, open-label, pilot randomized controlled trial enrolled 68 EGFR-mutated stage IIIB/IV NSCLC patients randomized 23 to the icotinib alone and chemotherapy + icotinib groups.RESULTS:
The median progression-free survival in the icotinib alone and chemotherapy + icotinib groups was 8.0 mo (95%CI 3.84-11.63) and 13.4 mo (95%CI 10.18-16.33), respectively (P = 0.0249). No significant differences were found in the curative effect when considering different cycles of chemotherapy or chemotherapy regimen (all P > 0.05).CONCLUSION:
A sequential combination of chemotherapy and EGFR-tyrosine kinase inhibitor is feasible for stage IV EGFR-mutated NSCLC patients.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Clinical_trials
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article